Coxib-inhibition of Duodenal Polyp Growth in FAP | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!

Coxib-inhibition of Duodenal Polyp Growth in FAP

study id #: NCT00844727

condition: Duodenal Polyposis

status: terminated


Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.

Drug: Rofecoxib
Drug: placebo

start date: September 2003

estimated completion: April 2004

last updated: July 6, 2011

phase of development: Phase 2, Phase 3

size / enrollment: 38

study design:
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

inclusion criteria:

• Eligible Sexes:

- FAP patient with previous colectomy and confirmed polyposis

exclusion criteria:
- Pregnancy
- Malignancy
- NSAID hypersensitivity

sponsor: Oslo University Hospital

trial center locations: Norway

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.